arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ACHIEVE LIFE SCIENCES, INC.

ACHV
$6.37 ▼ -0.62 (-8.87%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
68 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

ACHIEVE LIFE SCIENCES, INC. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $595.7M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC None
FCF / Share $-0.12 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-10.17M
↑ +20.7% —
FCF / Share Free cash flow per share
$-0.12
↑ +11.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
1
Cash Quality →
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters